Biogen is an American biotech company based in Cambridge, Massachusetts. The company uses recombinant DNA technology, also known as biotechnology. This makes it possible to produce human proteins and therefore medicinal products with the help of microorganisms. The company continues to develop new substances and works on improving already approved molecules.
According to Biogen's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 12.8647. At the end of 2021 the company had a P/E ratio of 23.0.
Year | P/E ratio | Change |
---|---|---|
2021 | 23.0 | 130.16% |
2020 | 9.99 | 6.16% |
2019 | 9.41 | -32.3% |
2018 | 13.9 | -47.92% |
2017 | 26.7 | 59.61% |
2016 | 16.7 | -16.06% |
2015 | 19.9 | -27.01% |
2014 | 27.3 | -23.12% |
2013 | 35.5 | 40.52% |
2012 | 25.3 | 17.15% |
2011 | 21.6 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 20.9 | 62.79% | ๐บ๐ธ USA |
![]() Pfizer PFE | 7.61 | -40.87% | ๐บ๐ธ USA |
![]() AbbVie ABBV | 23.6 | 83.48% | ๐บ๐ธ USA |
![]() Amgen AMGN | 19.0 | 47.55% | ๐บ๐ธ USA |
![]() Sanofi SNY | 16.0 | 24.03% | ๐ซ๐ท France |
![]() Gilead Sciences GILD | 30.1 | 133.78% | ๐บ๐ธ USA |
![]() Illumina ILMN | -8.34 | -164.80% | ๐บ๐ธ USA |
![]() Acorda Therapeutics
ACOR | -0.0791 | -100.61% | ๐บ๐ธ USA |
![]() Qiagen QGEN | 24.9 | 93.89% | ๐ณ๐ฑ Netherlands |
![]() Bio-Rad Laboratories BIO | -3.80 | -129.52% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.